Search - tctmd.com

Displaying 621 - 640 of 650

Sort: Relevancy | Date

News Daily News

Un Registro del Depto. de Veteranos confirma Beneficios a Largo plazo derivados de la Administración de Clopidogrel por encima de los 12 Meses

Caitlin E. Cox

June 11, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Industry News

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

May 15, 2012

News Industry News

OrbusNeich’s Combo Dual Therapy Stent™ Featured During Symposium at Angioplasty Summit TCTAP 2012

April 25, 2012

News Industry News

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

April 20, 2012

News Daily News

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

April 03, 2012

News Daily News

PRODIGY Published: No Advantage to Long-term Clopidogrel

April 03, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Conference News

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

November 21, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

News Industry News

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

November 09, 2011

News Conference News

ADAPT-DES: Risk of Early Stent Thrombosis in DES Predicted by Platelet Inhibition

November 09, 2011

News Industry News

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

November 08, 2011

News Industry News

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

November 08, 2011

News Industry News

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

November 08, 2011

News Conference News

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

November 08, 2011

News Conference News

Low Event Rates with EES Sustained at 2 Years

November 08, 2011

News Conference News

Bioabsorbable Polymers, Scaffolds Offer Permanent Advantages

November 08, 2011

Advertisement

Un Registro del Depto. de Veteranos confirma Beneficios a Largo plazo derivados de la Administración de Clopidogrel por encima de los 12 Meses

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

OrbusNeich’s Combo Dual Therapy Stent™ Featured During Symposium at Angioplasty Summit TCTAP 2012

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

PRODIGY Published: No Advantage to Long-term Clopidogrel

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

ADAPT-DES: Risk of Early Stent Thrombosis in DES Predicted by Platelet Inhibition

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

Patients with ACS and/or diabetes who show poor response to dual antiplatelet therapy

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

Low Event Rates with EES Sustained at 2 Years

Bioabsorbable Polymers, Scaffolds Offer Permanent Advantages

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content